Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
97 hedge funds and large institutions have $1.63B invested in Sio Gene Therapies Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 26 reducing their positions, and 13 closing their positions.
121% more call options, than puts
Call options by funds: $26.7M | Put options by funds: $12.1M
30% more capital invested
Capital invested by funds: $1.25B → $1.63B (+$372M)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
23% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 101 → 97 (-4)
6.47% less ownership
Funds ownership: 101.77% → 95.3% (-6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$28.3M |
| 2 |
BlackRock
New York
|
+$14M |
| 3 |
Credit Agricole
Montrouge Cedex,
France
|
+$12M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$5.04M |
| 5 |
PVI
Pura Vida Investments
New York
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$20M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.3M |
| 3 |
O
OppenheimerFunds
New York
|
-$3.66M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$2.36M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
-$1.97M |
SIOX Hedge Fund Activity: Q1 2017 in Review
97 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2017, worth a combined $1.63B — up 30% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SIOX positions and 13 closed out — a net gain of 3 holders — while 32 added to existing stakes and 26 trimmed.
The largest buyer was Primecap Management, adding an estimated $28.3M. The largest seller was Capital Research Global Investors, cutting an estimated $20M.
- 97 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2017, down from 101 in Q4 2016.
- Funds reported $1.63B of Sio Gene Therapies Inc. Common Stock stock for Q1 2017, up 30% quarter-over-quarter.
- 16 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2017 and 13 closed out, a net change of +3 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2017 was Primecap Management, an estimated $28.3M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2017 was Capital Research Global Investors, an estimated $20M sold.
Based on aggregated 13F filings for Q1 2017.